Disease Markers / 2015 / Article / Tab 1

Research Article

Aerobic Glycolysis as a Marker of Tumor Aggressiveness: Preliminary Data in High Grade Human Brain Tumors

Table 1

Demographic characteristics and medical history.

ParticipantAgeGenderPathology, WHO gradeLocationSurgery prior to the studyTreatment prior to the studyStatus at the time of studyAerobic glycolysis

157MGBM, IVR temporooccipitalNoneNoneNewly diagnosedElevated
271MGBM, IVR temporalResectionIMRT, TEMRecurrentElevated
369MGBM, IVL temporoparietalResectionIMRT, TEMRecurrentElevated
449MGBM, IVL temporalResectionIMRT, TEM, and AvastinRecurrentElevated
558MGBM, IVR occipitalResectionIMRT, TEMRecurrentElevated
642MPNET, IVL temporalResectionIMRT, Vincristine, and CisplatinRecurrentElevated
743MAA, IIIR frontalResectionIMRT, TEMRecurrentElevated
857FAOA, IIIL temporooccipitalBiopsyIMRT, TEMProgressionElevated
956MAOA, IIIL parietalBiopsyIMRT, TEMStable diseaseElevated
1057MPNET, IVR temporalResectionWBRT, TEMResidual/recurrentNot elevated
1129MAO, IIIL frontalResectionIMRT, TEMStable diseaseNot elevated
1230FAA, IIIL frontoparietalBiopsyNoneNewly diagnosedNot elevated
1343MFAD; GBM, IVR frontalNoneNoneFADAsymmetry
1440MAO, IIIL frontalResectionIMRT, TEMRecurrentElevated

M, male; F, female; WHO, World Health Organization; GBM, glioblastoma; PNET, primitive neuroectodermal tumor; AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; AO, anaplastic oligodendroglioma; FAD, familial Alzheimer’s disease; R, right; L, left; IMRT, intensity-modulated radiation therapy; WBRT, whole brain radiation therapy; TEM, Temozolomide.